Home › Schizophrenia
Schizophrenia clinical trials recruiting in the U.S.
105 studies for Schizophrenia are recruiting participants at sites across the United States.
Schizophrenia is a serious brain illness that can include hearing voices that aren't there and thinking others are trying to hurt them.
Cities with the most studies
- Atlanta, GA22 studies
- Chicago, IL20 studies
- Little Rock, AR19 studies
- Hollywood, FL15 studies
- Boston, MA14 studies
- San Diego, CA13 studies
- Houston, TX13 studies
- New York City, NY13 studies
- Hialeah, FL13 studies
- Austin, TX13 studies
- Garden Grove, CA12 studies
- Germantown, MD11 studies
- Miami, FL10 studies
- Camden, NJ10 studies
- Richardson, TX9 studies
- Los Angeles, CA8 studies
- Anaheim, CA8 studies
- Inglewood, CA8 studies
- Johns Creek, GA8 studies
- Cincinnati, OH8 studies
- Grand Prairie, TX8 studies
- El Cajon, CA8 studies
- Dallas, TX8 studies
- Philadelphia, PA8 studies
- Cambridge, MA8 studies
- Pittsburgh, PA7 studies
- Springdale, AR7 studies
- West Palm Beach, FL7 studies
- Staten Island, NY7 studies
- Las Vegas, NV7 studies
- St. Louis, MO7 studies
- New Haven, CT6 studies
- Queens, NY6 studies
- Chino, CA6 studies
- Orlando, FL6 studies
- Richmond, VA6 studies
- Nashville, TN6 studies
- The Bronx, NY6 studies
- Torrance, CA6 studies
- Orange, CA6 studies
By state
- Alabama4 studies
- Arizona4 studies
- Arkansas21 studies
- California44 studies
- Colorado3 studies
- Connecticut9 studies
- Florida26 studies
- Georgia29 studies
- Illinois25 studies
- Maryland17 studies
- Massachusetts22 studies
- Michigan5 studies
- Minnesota4 studies
- Mississippi3 studies
- Missouri10 studies
- Nebraska6 studies
- Nevada7 studies
- New Jersey13 studies
- New York23 studies
- North Carolina3 studies
- Ohio18 studies
- Oklahoma4 studies
- Pennsylvania15 studies
- Tennessee6 studies
- Texas34 studies
- Virginia6 studies
- Washington8 studies
Recently updated studies
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 28, 2026 · NCT07686263A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
RecruitingPhase 1
Ages 18 to 55 · All sexes · Updated Sep 28, 2026 · NCT07615426Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 25, 2026 · NCT07227818NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 25, 2026 · NCT07114874Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
RecruitingPhase 3
Ages 5 to 17 · All sexes · Updated Sep 25, 2026 · NCT06229210NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 25, 2026 · NCT07105098Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
RecruitingPhase 2
Ages 18 to 60 · All sexes · Updated Sep 23, 2026 · NCT07680946State Representation in Early Psychosis 2
RecruitingObservational studyHealthy volunteers welcome
Ages 15 to 45 · All sexes · Updated Sep 22, 2026 · NCT07834203A Study of Brenipatide in Adult Participants With Schizophrenia
RecruitingPhase 2
Ages 18 to 55 · All sexes · Updated Sep 22, 2026 · NCT07410507A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
RecruitingPhase 3
Ages 5 to 17 · All sexes · Updated Sep 22, 2026 · NCT07424404A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07105111A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia
RecruitingPhase 1
Ages 18 to 55 · All sexes · Updated Sep 17, 2026 · NCT07734493Circuitry-Guided Smoking Cessation in Schizophrenia (UH3)
Recruiting
Ages 22 to 65 · All sexes · Updated Sep 16, 2026 · NCT05276050A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Sep 15, 2026 · NCT0714591852-week Open Label Safety-Tolerability Study
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 9, 2026 · NCT07369154A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
RecruitingPhase 3
Ages 13 to 17 · All sexes · Updated Sep 4, 2026 · NCT07288567Genetic Basis of the Risk and Consequences of Cannabis Exposure in Humans
RecruitingPhase 1Healthy volunteers welcome
Ages 21 to 60 · All sexes · Updated Sep 2, 2026 · NCT06058702A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
RecruitingPhase 1
Ages 18 to 55 · All sexes · Updated Sep 2, 2026 · NCT07061288A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Sep 1, 2026 · NCT07459647Overnight Thalamic TES-TI to Modulate Sleep Spindles in Individuals With Schizophrenia Spectrum Disorders and Matched Healthy Controls
RecruitingHealthy volunteers welcome
Ages 18 to 50 · All sexes · Updated Aug 31, 2026 · NCT07680114Activities to Change Your Mood: A Test of the Acceptability and Initial Efficacy in Clinical Samples and Healthy Controls
RecruitingHealthy volunteers welcome
Ages 18 to 65 · All sexes · Updated Aug 31, 2026 · NCT06911723Cerebellar Modulation of Cognition in Psychosis
Recruiting
Ages 18 to 55 · All sexes · Updated Aug 20, 2026 · NCT06107764Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT07101094Enhancing Veteran-Clinical Collaboration in VA PRRCs
Recruiting
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT06898879Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT07379827From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.